Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

NCT01047683 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

229

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertriglyceridemia

Interventions

DRUG: AMR101 (ethyl icosapentate) - 4 g/day
DRUG: AMR101 (ethyl icosapentate) - 2 g/day
DRUG: Placebo

Sponsor

Amarin Pharma Inc.